A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb‐004) in metastatic soft‐tissue sarcomas
Robin L. Jones(Seattle Cancer Care Alliance), Robert G. Maki(Memorial Sloan Kettering Cancer Center)
Cited by 27
Related Papers
Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas
|Journal of Clinical Oncology|2009|573
Malignant Peripheral Nerve Sheath Tumors
|The Oncologist|2014|361